Cargando…
Bone metastasis risk factors in breast cancer
Bone is the single most frequent site for bone metastasis in breast cancer patients. Patients with bone-only metastasis have a fairly good prognosis when compared with patients with visceral disease. Nevertheless, cancer-induced bone disease carries an important risk of developing skeletal related e...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295847/ https://www.ncbi.nlm.nih.gov/pubmed/28194227 http://dx.doi.org/10.3332/ecancer.2017.715 |
_version_ | 1782505507720790016 |
---|---|
author | Pulido, Catarina Vendrell, Inês Ferreira, Arlindo R Casimiro, Sandra Mansinho, André Alho, Irina Costa, Luís |
author_facet | Pulido, Catarina Vendrell, Inês Ferreira, Arlindo R Casimiro, Sandra Mansinho, André Alho, Irina Costa, Luís |
author_sort | Pulido, Catarina |
collection | PubMed |
description | Bone is the single most frequent site for bone metastasis in breast cancer patients. Patients with bone-only metastasis have a fairly good prognosis when compared with patients with visceral disease. Nevertheless, cancer-induced bone disease carries an important risk of developing skeletal related events that impact quality of life (QoL). It is therefore particularly important to stratify patients according to their risk of developing bone metastasis. In this context, several risk factors have been studied, including demographic, clinicopathological, genetic, and metabolic factors. Most of them show conflicting or non-definitive associations and are not validated for clinical use. Nonetheless, tumour intrinsic subtype is widely accepted as a major risk factor for bone metastasis development and luminal breast cancer carries an increased risk for bone disease. Other factors such as gene signatures, expression of specific cytokines (such as bone sialoprotein and bone morphogenetic protein 7) or components of the extracellular matrix (like bone crosslinked C-telopeptide) might also influence the development of bone metastasis. Knowledge of risk factors related with bone disease is of paramount importance as it might be a prediction tool for triggering the use of targeted agents and allow for better patient selection for future clinical trials. |
format | Online Article Text |
id | pubmed-5295847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-52958472017-02-13 Bone metastasis risk factors in breast cancer Pulido, Catarina Vendrell, Inês Ferreira, Arlindo R Casimiro, Sandra Mansinho, André Alho, Irina Costa, Luís Ecancermedicalscience Review Bone is the single most frequent site for bone metastasis in breast cancer patients. Patients with bone-only metastasis have a fairly good prognosis when compared with patients with visceral disease. Nevertheless, cancer-induced bone disease carries an important risk of developing skeletal related events that impact quality of life (QoL). It is therefore particularly important to stratify patients according to their risk of developing bone metastasis. In this context, several risk factors have been studied, including demographic, clinicopathological, genetic, and metabolic factors. Most of them show conflicting or non-definitive associations and are not validated for clinical use. Nonetheless, tumour intrinsic subtype is widely accepted as a major risk factor for bone metastasis development and luminal breast cancer carries an increased risk for bone disease. Other factors such as gene signatures, expression of specific cytokines (such as bone sialoprotein and bone morphogenetic protein 7) or components of the extracellular matrix (like bone crosslinked C-telopeptide) might also influence the development of bone metastasis. Knowledge of risk factors related with bone disease is of paramount importance as it might be a prediction tool for triggering the use of targeted agents and allow for better patient selection for future clinical trials. Cancer Intelligence 2017-01-24 /pmc/articles/PMC5295847/ /pubmed/28194227 http://dx.doi.org/10.3332/ecancer.2017.715 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Pulido, Catarina Vendrell, Inês Ferreira, Arlindo R Casimiro, Sandra Mansinho, André Alho, Irina Costa, Luís Bone metastasis risk factors in breast cancer |
title | Bone metastasis risk factors in breast cancer |
title_full | Bone metastasis risk factors in breast cancer |
title_fullStr | Bone metastasis risk factors in breast cancer |
title_full_unstemmed | Bone metastasis risk factors in breast cancer |
title_short | Bone metastasis risk factors in breast cancer |
title_sort | bone metastasis risk factors in breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295847/ https://www.ncbi.nlm.nih.gov/pubmed/28194227 http://dx.doi.org/10.3332/ecancer.2017.715 |
work_keys_str_mv | AT pulidocatarina bonemetastasisriskfactorsinbreastcancer AT vendrellines bonemetastasisriskfactorsinbreastcancer AT ferreiraarlindor bonemetastasisriskfactorsinbreastcancer AT casimirosandra bonemetastasisriskfactorsinbreastcancer AT mansinhoandre bonemetastasisriskfactorsinbreastcancer AT alhoirina bonemetastasisriskfactorsinbreastcancer AT costaluis bonemetastasisriskfactorsinbreastcancer |